Andrew J. Last
CIK 1485088 · EVP, Chief Operating Officer · last filed 2026-07-06
Andrew J. Last is an EVP, Chief Operating Officer who has filed 66 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing shows the insider had shares withheld for taxes covering $43.8K of OCX on Jul 6, 2026. Across all open-market trades the lifetime net is −$3.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.56M
4
66
-$3.84M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (OCX) Delisted | Director | 58,752 | $3.20 | $188.0K | $17.4K | 17 | 2026-07-06 |
| BIO.B | EVP, Chief Operating Officer | 10,559 | $337.00 | $3.56M | -$2.62M | 14 | 2024-09-10 |
| PRECIGEN, INC. (XON) Delisted | Chief Operating Officer | 4,000 | — | — | $64.2K | 3 | 2017-11-15 |
| AFFYMETRIX INC (AFFX) Delisted | EVP, Chief Operating Officer | 0 | — | — | -$1.30M | 29 | 2016-04-01 |
Recent Filings
66 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Tax (F) | −7,700 | -$43.8K | EDGAR |
| 2026-06-15 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | +26,943 | $0 | EDGAR |
| 2025-07-03 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2024-11-06 | BIO | Notice (144) | −3,000 | -$1.12M | EDGAR |
| 2024-09-12 | BIO | Notice (144) | −1,600 | -$514.5K | EDGAR |
| 2024-09-10 | BIO.B | Mixed | — | -$92.1K | EDGAR |
| 2024-09-06 | BIO | Notice (144) | −3,000 | -$989.8K | EDGAR |
| 2024-09-04 | BIO.B | Mixed | +1,801 | -$625.4K | EDGAR |
| 2024-07-03 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-30 | BIO.B | Mixed | +643 | -$98.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.